Welcome to our dedicated page for DECOY THERAPEUTICS SEC filings (Ticker: DCOY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Decoy Therapeutics Inc. (DCOY) is intended to provide access to the company’s regulatory disclosures once they are available on EDGAR. As a preclinical-stage biotechnology company in peptide-conjugate therapeutics, Decoy’s future filings are expected to explain its IMP3ACT platform, early-stage antiviral and oncology programs, and related risks and uncertainties in greater detail.
When Decoy files annual reports on Form 10-K and quarterly reports on Form 10-Q, these documents typically describe the company’s business overview, research and development focus, intellectual property, financing arrangements and risk factors. For a company like Decoy, such filings can be important for understanding how it presents its peptide-conjugate technology, preclinical data, and design-for-manufacturing strategy to regulators and investors.
Current and future Form 8-K filings may cover material events such as collaborations, funding arrangements or key developments related to its Global Access Commitment Agreement and manufacturing platform for peptide-conjugate antivirals. Over time, proxy statements on Schedule 14A and Form 4 insider transaction reports can offer additional context on governance and equity ownership, once they exist for the company.
On Stock Titan, Decoy’s SEC filings will be supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping readers interpret technical and legal language. Real-time updates from EDGAR, combined with AI explanations of 10-Ks, 10-Qs, 8-Ks and potential Form 4 filings, are designed to make it easier to follow how Decoy’s disclosures evolve alongside its peptide-conjugate antiviral and oncology programs.
Decoy Therapeutics, Inc. has regained compliance with Nasdaq’s Listing Rule 5550(a)(2), known as the Minimum Bid Price Requirement. After receiving a Nasdaq notice in December 2025 for trading below $1.00, the company implemented a reverse stock split effective March 6, 2026.
The shares began trading on a split-adjusted basis on March 9, 2026, and the common stock then maintained a bid price of at least $1.00 for 10 consecutive business days, closing at $7.47 on March 20, 2026. On March 31, 2026, a Nasdaq Hearings Panel confirmed Decoy is in compliance with all applicable continued listing requirements.
The company will remain under a Mandatory Panel Monitor until March 31, 2027, meaning Nasdaq will closely review any future bid-price noncompliance and could initiate delisting proceedings if the minimum bid price standard is again breached.
Decoy Therapeutics Inc. files its annual report describing a preclinical-stage biotechnology business built around the AI- and machine-learning–enabled IMP3ACT™ peptide conjugate platform. The company is developing Designable Multi-Antivirals targeting conserved viral fusion mechanisms, led by a nasally inhaled pan-coronavirus prophylactic for immunocompromised patients and a planned broad respiratory antiviral for flu, COVID-19, and RSV.
The report details the November 2025 merger with Legacy Decoy, a subsequent name and ticker change, and two reverse stock splits (1-for-15 in 2025 and 1-for-12 in 2026) used alongside capital raises to maintain Nasdaq listing compliance. Management highlights substantial doubt about the company’s ability to continue as a going concern, ongoing operating losses, reliance on future financings and non‑dilutive grants, and early-stage programs that have not yet generated product revenue.
Decoy Therapeutics Inc. is implementing a 1-for-12 reverse stock split of its common stock to help regain compliance with Nasdaq’s minimum $1.00 bid price requirement. The split becomes effective at 5:00 p.m. Eastern Time on March 6, 2026.
Every 12 issued and outstanding shares will be combined into one share, reducing outstanding common stock from approximately 6.38 million shares to approximately 532,000 shares, while authorized common shares remain at 100 million and par value stays $0.0001 per share. Trading on a split-adjusted basis on the Nasdaq Capital Market under the symbol DCOY and new CUSIP 79400X602 is expected to begin March 9, 2026.
All outstanding options, warrants, restricted stock units and shares reserved under equity plans will be adjusted proportionately. Fractional shares will be rounded down and paid in cash based on the March 6, 2026 closing price.
Decoy Therapeutics Inc. reported that stockholders approved all matters presented at a virtual special meeting held on February 24, 2026. The meeting had a quorum with 2,696,758 common shares represented. Stockholders approved the 2026 Equity Incentive Plan, providing a new framework for equity-based compensation.
They also approved a reverse stock split of outstanding common stock at a ratio between 1-for-4 and 1-for-15, with the exact ratio to be set at the board’s discretion. An adjournment proposal was approved as well, but the meeting did not need to be adjourned because sufficient votes were obtained for the main proposals.
Decoy Therapeutics Inc. investor reports a 9.9% passive stake. CVI Investments, Inc. and Heights Capital Management, Inc. jointly report beneficial ownership of 708,565 shares of Decoy Therapeutics common stock, all issuable upon exercise of warrants.
Their ownership represents 9.9% of the common stock, based on 6,384,177 shares outstanding as of December 26, 2025, as cited from the company’s definitive proxy statement. The warrants are subject to a 9.99% beneficial ownership cap, limiting exercise if it would push total holdings above that level. The filers certify the securities were not acquired to change or influence control of the company.
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, is asking stockholders at a virtual special meeting on February 24, 2026 to approve a new 2026 Equity Incentive Plan and a reverse stock split.
The 2026 plan would authorize 1,100,000 shares initially, with automatic annual increases of 6% of shares outstanding on December 31, 2026 and 5% each January 1 from 2028 through 2036 unless the board reduces or cancels an increase. As of December 26, 2025, ten employees and six non-employee directors would be eligible and the stock closed at $0.6573 per share.
The reverse split would combine shares at a ratio between 1‑for‑4 and 1‑for‑15, leaving 100,000,000 authorized shares but reducing the 6,384,177 shares outstanding (for example to 1,596,044 at 1‑for‑4). The board’s goal is to raise the share price to meet Nasdaq’s initial listing standards after a merger with Decoy, following a Nasdaq notice that the stock has traded below the $1.00 minimum bid and a pending delisting appeal.
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is changing its corporate identity. The company filed a Certificate of Amendment in Delaware to change its legal name to Decoy Therapeutics Inc., effective January 8, 2026, a step that did not require a stockholder vote and does not alter stockholder rights.
In connection with the name change, the board approved Second Amended and Restated Bylaws reflecting the new name. The company also announced that its common stock, previously trading under the symbol “SLRX”, is expected to begin trading on the Nasdaq Capital Market under the new ticker “DCOY” on January 8, 2026. A new corporate website at decoytx.com, including investor relations information and links to SEC filings, is being launched as part of this rebranding.